Oct. 2, 2016: 
Gene Therapy: GenSight is recruiting patients with Leber's Hereditary Optic Neuropathy (with the ND4/G1178A gene mutation) for gene therapy in a Phase III clinical trial of GS010. There are two arms to the trial: Rescue and Reverse. RESCUE is recruiting individuals whose vision loss commenced within 6 months prior to screening for the trial, while REVERSE is recruiting individuals whose vision loss commenced between 6-12 months prior to screening. More information on the GS010 trials is available at clinicaltrials.gov.
Patients interested in enrolling in the trial should contact Scott Uretsky, MD-Director of Clinical Development Neuro-Ophthalmology: suretsky@gensight-biologics.com